Genmab's DARZALEX Royalties Surge to $4.2B in Q3 2026
Event summary
- Genmab reported $4.24B in worldwide net sales of DARZALEX in Q3 2026, up from $2.53B in the U.S. and $1.71B internationally.
- Royalties stem from Genmab's exclusive license agreement with Johnson & Johnson for daratumumab products.
- Sales include both intravenous and subcutaneous formulations (DARZALEX FASPRO® in the U.S.).
- Genmab has received royalties on DARZALEX sales since the drug's commercialization.
The big picture
Genmab's strong Q3 2026 DARZALEX sales reflect the continued dominance of monoclonal antibody therapies in oncology. The performance underscores the value of Genmab's licensing model with Johnson & Johnson, which has successfully commercialized daratumumab across multiple formulations. As biotech partnerships evolve, Genmab's ability to sustain royalty growth will depend on both DARZALEX's market longevity and the success of its internal pipeline.
What we're watching
- Market Dynamics
- How sustained demand for DARZALEX will impact Genmab's royalty income trajectory.
- Competitive Pressures
- Whether Johnson & Johnson can maintain DARZALEX's market share against emerging therapies.
- Pipeline Development
- The pace at which Genmab advances its late-stage clinical pipeline to diversify revenue streams.
Related topics
